These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 20211755)

  • 1. The nasty surprise of a complex drug-drug interaction.
    Bode C
    Drug Discov Today; 2010 May; 15(9-10):391-5. PubMed ID: 20211755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
    Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug safety. Notes regarding drug surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2003; 27(5):331-5. PubMed ID: 14576924
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
    Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
    Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
    J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.
    Boulenc X; Barberan O
    Drug Metabol Drug Interact; 2011; 26(4):147-68. PubMed ID: 22149659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
    Zhang L; Reynolds KS; Zhao P; Huang SM
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):134-45. PubMed ID: 20045016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
    Bachmann KA; Lewis JD
    Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
    Grime KH; Bird J; Ferguson D; Riley RJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic screening for pharmacokinetic interactions during drug development.
    Fuhr U; Weiss M; Kroemer HK; Neugebauer G; Rameis H; Weber W; Woodcock BG
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):139-51. PubMed ID: 8861732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human radiolabeled mass balance studies: objectives, utilities and limitations.
    Penner N; Klunk LJ; Prakash C
    Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
    Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
    Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.